Publications by authors named "Franco Morelli"

Claim this Profile
T
Time to metastasis as a prognostic factor in metastatic urothelial carcinoma: results from the ARON-2 study.
Renate Pichler, Gerald Klinglmair, Kirstin Binz, Enrique Grande, Alina Pirshtuk, Franco Morelli

Clin Exp Metastasis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study.
Matteo Santoni, Thomas Büttner, Pasquale Rescigno, Ondrej Fiala, Nicolò Cavasin, Franco Morelli

Eur Urol Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 Study.
Brigida Anna Maiorano, Martina Catalano, Chiara Mercinelli, Giandomenico Roviello, Marco Maruzzo, Franco Morelli

Clin Genitourin Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience.
Mimma Rizzo, Franco Morelli, Yüksel Ürün, Sebastiano Buti, Se Hoon Park

Cancer Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab.
Alessandra Damassi, Malvina Cremante, Alessio Signori, Sara Elena Rebuzzi, Andrea Malgeri, Franco Morelli

Immunotherapy· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study.
Carlo Messina, Martina Catalano, Giandomenico Roviello, Annalice Gandini, Marco Maruzzo, Franco Morelli

Cancer Immunol Immunother· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study.
Martina Catalano, Sara Elena Rebuzzi, Marco Maruzzo, Ugo De Giorgi, Sebastiano Buti, Franco Morelli

Front Immunol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.
Francesco Massari, Matteo Santoni, Hideki Takeshita, Yohei Okada, Jose Carlos Tapia, Franco Morelli

Cancer Immunol Immunother· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical utility of Next Generation Sequencing of plasma cell-free DNA for the molecular profiling of patients with NSCLC at diagnosis and disease progression.
Marzia Del Re, Giovanna Irene Luculli, Iacopo Petrini, Andrea Sbrana, Vieri Scotti, Franco Morelli

Transl Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Matteo Santoni, Sebastiano Buti, Zin W Myint, Marco Maruzzo, Roberto Iacovelli, Franco Morelli

Eur Urol Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: analysis of the Meet-URO 15 study.
Veronica Murianni, Alessio Signori, Sebastiano Buti, Sara Elena Rebuzzi, Davide Bimbatti, Franco Morelli

Front Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study.
Ondřej Fiala, Sebastiano Buti, Hideki Takeshita, Yohei Okada, Francesco Massari, Franco Morelli

Cancer Immunol Immunother· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab.
Martina Catalano, Sara Elena Rebuzzi, Marco Maruzzo, Ugo De Giorgi, Sebastiano Buti, Franco Morelli

JAMA Netw Open· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations.
Camillo Porta, Aristotelis Bamias, Roubini Zakopoulou, Zin W Myint, Nicolò Cavasin, Franco Morelli

Minerva Urol Nephrol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study.
Sara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, Annalice Gandini, Giuseppe Fornarini, Franco Morelli

J Transl Med· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis.
Sara Elena Rebuzzi, Alessio Signori, Marco Stellato, Daniele Santini, Marco Maruzzo, Franco Morelli

Front Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of a First-Line Chemotherapy Tailored by G8 Score in Elderly Metastatic or Locally Advanced Gastric and Gastro-Esophageal Cancer Patients: A Real-World Analysis.
Ina Valeria Zurlo, Carmelo Pozzo, Antonia Strippoli, Samantha Mignogna, Michele Basso, Franco Morelli

Geriatrics (Basel)· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study.
Cristina Masini, Cinzia Iotti, Ugo De Giorgi, Roberto Salvatore Bellia, Sebastiano Buti, Franco Morelli

Eur Urol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of grade 3-4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis.
Alessandro Rizzo, Veronica Mollica, Sara Merler, Franco Morelli, Giulia Sorgentoni

Expert Opin Drug Metab Toxicol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents.
Alessandro Rizzo, Marco Oderda, Veronica Mollica, Sara Merler, Franco Morelli

Anticancer Drugs· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of Total, PTEN, and AR-V7 Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide.
Giuseppe Di Lorenzo, Silvia Zappavigna, Felice Crocetto, Mario Giuliano, Dario Ribera, Franco Morelli

Clin Genitourin Cancer· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak.
Melissa Bersanelli, Sebastiano Buti, Mimma Rizzo, Alessio Cortellini, Carlo Cattrini, Franco Morelli

Ther Adv Urol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial.
Orazio Caffo, Cinzia Ortega, Franco Nolè, Donatello Gasparro, Claudia Mucciarini, Franco Morelli

Eur J Cancer· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study).
Sara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, Marco Maruzzo, Ugo De Giorgi, Franco Morelli

Ther Adv Med Oncol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A CT-Based Radiomic Signature Can Be Prognostic for 10-Months Overall Survival in Metastatic Tumors Treated with Nivolumab: An Exploratory Study.
Valentina D A Corino, Marco Bologna, Giuseppina Calareso, Lisa Licitra, Mariagrazia Ghi, Franco Morelli

Diagnostics (Basel)· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis